AI-Driven Prediction of Stem Cell Senescence and Regenerative Potential Through Epigenetic and Transcriptomic Profiling

Abstract

The therapeutic promise of stem cell-based regenerative medicine depends increasingly on the ability to distinguish cells that retain regenerative capacity from those that have entered senescence or are drifting toward functional exhaustion. Epigenetic and transcriptomic profiling offer a high-dimensional window into these states, but the resulting data are heterogeneous, noisy, batch-sensitive, and difficult to interpret at the scale required for clinical decision support. This paper examines the system-level design of artificial intelligence platforms that predict stem cell senescence and regenerative potential from epigenetic and transcriptomic measurements. It argues that prediction is not merely a modeling problem but an infrastructural, governance, and translational problem involving data provenance, multi-omic integration, model robustness, fairness across donor populations, regulatory accountability, and long-term sustainability. The discussion first reviews the biological foundations of senescence and stemness, then analyzes data architectures for methylation, chromatin accessibility, histone modification, and single-cell transcriptomic profiling. It subsequently considers model classes ranging from regularized statistical learners to deep representation models and graph-based integration strategies. The paper then develops an architecture for clinical and research deployment, emphasizing modularity, uncertainty quantification, federated learning, validation, and human oversight. Cross-domain comparisons with oncology, aging biomarkers, and precision medicine illustrate recurring trade-offs between predictive performance and interpretability, between centralized data consolidation and privacy-preserving federation, and between rapid translational ambition and durable evidentiary standards. The conclusion contends that trustworthy AI for stem cell senescence requires not only accurate predictive models but also transparent data ecosystems, representative cohorts, reproducible pipelines, equitable access, and policy frameworks that align innovation with patient safety and scientific accountability.